This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

150 results

Diagnostic proposals for acute uncomplicated cystitis in women

02-10-2020
There is currently no generally accepted strategy for the clinical diagnosis of acute uncomplicated cystitis. This study evaluated the diagnostic value of recently proposed draft guidelines for the clinical diagnosis of this condition by the US FDA and EMA using the previously validated Acute Cystitis Symptom Score (ACSS).

The difference diabetes can make with regard to UTIs

02-10-2020
People with diabetes are more prone to UTIs due to immune system and bladder dysfunction than people without diabetes. In light of controversies regarding the incidence, clinical pattern and microbiology of UTIs in diabetes patients, this prospective study sought to compare these aspects of UTI in patients with and without diabetes.

Appropriateness of fluoroquinolone use in acute uncomplicated cystitis

02-10-2020
It is recommended to avoid fluoroquinolones as first-line treatment for uncomplicated cystitis due to the risk of serious side effects but their use in this setting is still widespread. This study evaluated the extent and appropriateness of empiric fluoroquinolone use for uncomplicated cystitis compared with that of nitrofurantoin and identified predictors of empiric fluoroquinolone use for this indication.

Diagnosing and managing UTI in children

02-10-2020
UTI is a common infection in children but can be a challenge to diagnose. In addition, controversies exist regarding its investigation and management and recommendations vary across guidelines. This review paper gives an overview of these aspects with highlights from recent evidence and guideline recommendations.

The state of antibiotic resistance in community-acquired bacterial pneumonia

22-09-2020
The burden of community-acquired pneumonia (CAP) is set to increase with ageing populations and with it the need for appropriate antibiotic prescribing in the face of increasing bacterial resistance. This review provides an update on the epidemiology of bacterial CAP and the patterns of antibiotic resistance around the world.

Enhancing health literacy to improve antimicrobial stewardship

22-09-2020
Patient health literacy is an important factor that impacts antimicrobial stewardship (AMS) in the community. Using a Centers for Disease Control and Prevention (CDC) framework, the authors of this paper describe four core elements for enhancing AMS health literacy in the outpatient setting.

Community-acquired serious bacterial infections of early infancy

22-09-2020
Serious bacterial infections (SBIs) occur more frequently in infants aged ≤90 days than in other paediatric groups and are increasingly due to multi-drug-resistant organisms (MDROs). This study assessed the epidemiology and bacteriology of SBIs in early infancy and compared the characteristics and outcomes of infections due to MDROs versus non-MDROs.

Using antibiotics wisely in the community

22-09-2020
Overuse of antibiotics for respiratory tract infection (RTI) and urinary tract infection (UTI) is widespread in primary care and long-term care settings, respectively. This paper describes the Using Antibiotics Wisely campaign that sought to boost antimicrobial stewardship among community prescribers in Canada. Prescribers were enlisted to develop practice change statements to support the appropriate use of antibiotics for RTIs and UTIs in the community.

Updates Overview

16-01-2018
Who we are: our mission and global narrative story

January

15-01-2018

Home|Healthcare Professionals

GSKpro is exclusively created for healthcare professionals to provide GSK product related information, services and support.

INFANRIX HEXA

Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b vaccine (adsorbed) <br>Vaccines

Kivexa

Abacavir / Lamivudina<br> VIH

Kivexa

Abacavir sulfate-lamivudine<br> HIV

Lamictal

Lamotrigina<br> SNC

Lamictal

Lamotrigine<br> Central Nervous System

INFANRIX HEXA

Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b vaccine (adsorbed) <br>Vaccines

Ventolin

Salbutamo<br> Respiratorio

Ventolin

Salbutamol<br> Respiratory

Avamys

Furoato de fluticasona<br> Respiratorio

Avamys

Fluticasone furoate<br> Respiratory

Boostrix

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed<br> Vaccines

Anoro

Umeclidinio/Vilanterol<br> Respiratorio

Anoro

Umeclidinium/Vilanterol<br> Respiratory

Dermovate

Clobetasol propionate<br> Dermatology

Dermovate

Clobetasol propionate<br> Dermatology

Tivicay

Dolutegravir<br> HIV

Zinnat Granules for Oral Suspension

Cefuroxime axetil</br>Anti-infective

Betnovate

Valerato de Betametasona<br> Dermatología

Betnovate

Betamethasone valerate<br> Dermatology

Relvar

Furoato de fluticasone / vilanterol<br> Respiratorio

Relvar

Fluticasone furoate/vilanterol<br> Respiratory

Duodart

Dutasterida/Tamsulosina<br> Urología

Duodart

Dutasteride/Tamsulosin HCI<br> Urology

Cutivate

Propionato de Fluticasona<br> Dermatología

Cutivate

Fluticasone propionate<br> Dermatology

Paxil

Paroxetina<br> SNC

Paxil

Paroxetine<br> Central Nervous System

Zyrtec

Cetirizine dihydrochloride</br>Respiratory

Seretide

Salmeterol/Propionato de fluticasona<br> Respiratorio

Seretide

Salmeterol/fluticasone propionate<br> Respiratory

Synflorix

Pneumococcal polysaccharide conjugate vaccine (adsorbed)<br> Vaccines

Keppra

Leveritacetam<br> SNC

Keppra

Levetiracetam<br> Central Nervous System

Zentel

Albendazole</br>Gastroenterology

Augmentin

Amoxicillin/ Clavulanic Acid<br> Anti-infectives

Flixotide

Propionato de Fluticasona<br> Respiratorio

Flixotide

Fluticasone Propionate<br> Respiratory

Rotarix

Vacunacontra rotavirus<br> Vacunas

Rotarix

Oral rotavirus vaccine<br> Vaccines

Sitemap

GlaxoSmithKline (GSK) UK healthcare professional website site map.

Search Results

GlaxoSmithKline (GSK) UK healthcare professional website search results.

EAU 2019 Highlights

EAU 2019 Highlights

Paxil/Seroxat

Paroxetine <br> Central Nervous System

Varilrix

Varicella vaccine</br>Vaccines

Priorix

Measles, mumps and rubella vaccine</br>Vaccines

Twinrix

Inactivated hepatitis A and rDNA hepatitis B vaccine (adsorbed)</br>Vaccines

Engerix B

Hepatitis B (rDNA) vaccine (adsorbed) </br>Vaccines

Havrix

Inactivated hepatitis A vaccine</br>Vaccines

Cookie Policy

Cookie information for users

Boostrix

Vacuna combinada de difteria, tétanos y tosferina acelular Para niños y adultos<br> Vacunas

Bactroban

Salmeterol/Propionato de fluticasona<br> Respiratorio

Bactroban

Mupirocin<br> Dermatology

Augmentin

Amoxicilina/ Ácido Clavulánico<br> Antiinfecciosos

Shingrix

Zoster vaccine recombinant, adjuvanted<br> Vaccine

Shingrix

Zoster vaccine recombinant, adjuvanted<br>Vaccine

Susceptibility

Augmentin Susceptibility

Guidelines

Augmentin Guidelines

Efficacy

Augmentin Efficacy

homepage

amoxicillin-clavulanate<br>Anti infectives

Augmentin

amoxicillin-clavulanate<br>Anti infectives

Shingrix

Zoster vaccine recombinant, adjuvanted<br>Vaccine

Recommendations

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is recommended by the CDC for the prevention of shingles (herpes zoster) and related complications for immunocompetent adults aged ≥50 years.

SHINGRIX in your Practice

SHINGRIX in your Practice

Home

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) product information and resources to support HCPs in their daily practice.

Immunocompromised Patients

SHINGRIX information for UK healthcare professionals only

Shingrix Risk of Shingles

Shingrix (Zoster Vaccine Recombinant, Adjuvanted) What is the Risk of Shingles

Clinical Data: Safety

The safety of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) was extensively studied in 2 large phase 3 clinical trials

Shingrix Efficacy Against Shingles

Shingrix (Zoster Vaccine Recombinant, Adjuvanted) Data showing the Efficacy of Shingrix Against Shingles

Patient Profiles

Is SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) right for your patients? Nearly everyone ≥50 years old needs shingles protection

Scientific Rationale

Recommend the shingles vaccine specifically formulated to address age-related decline in immunity

SHINGRIX in your Practice

Read about SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) dosing and administration details, information to share with patients, and guidance for series completion

No results. Why not try:

  • Checking the spelling of the search term
  • Trying a different search term
  • Resetting or revising the filter settings (if you used filters to do this search)

show more